Submitted by Anonymous (not verified) on 10 October 2023 - 8:53
Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Esophageal Squamous Cell Carcinoma, Date of authorisation: 15/09/2023, Status: Authorised
Source: